Jalal K Ghali

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. doi request reprint Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia
    Jalal K Ghali
    Wayne State University, Detroit, Mich, USA
    Circulation 117:526-35. 2008
  2. ncbi request reprint The influence of symptoms and device detected atrial tachyarrhythmias on medical management: insights from A-HIRATE
    Jalal K Ghali
    University Health Center, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Pacing Clin Electrophysiol 30:850-7. 2007
  3. ncbi request reprint Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia
    Jalal K Ghali
    Division of Cardiology, Wayne State University, 4201 St Antoine, Detroit, Michigan 48201, USA
    J Clin Endocrinol Metab 91:2145-52. 2006
  4. ncbi request reprint Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial
    Jalal K Ghali
    University Health Center, Wayne State University, Detroit, MI 48201, USA
    Am J Cardiovasc Drugs 7:373-80. 2007
  5. doi request reprint Sex differences in response to chronic heart failure therapies
    Jalal K Ghali
    University Health Care Center, Wayne State University, 4201 St Antoine, 2E, Detroit, MI 48201, USA
    Expert Rev Cardiovasc Ther 6:555-65. 2008
  6. doi request reprint Mechanisms, risks, and new treatment options for hyponatremia
    Jalal K Ghali
    Wayne State University, Detroit, Michigan, USA
    Cardiology 111:147-57. 2008
  7. doi request reprint Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial
    Jalal K Ghali
    Wayne State University, Detroit, MI 48201, USA
    J Card Fail 14:718-23. 2008
  8. ncbi request reprint Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)
    Marie Galvao
    Congestive Heart Failure Program, Division of Cardiology, Montefiore Medical Center, 7th Floor, 3400 Bainbridge Avenue, Bronx, NY 10467, USA
    J Card Fail 12:100-7. 2006
  9. doi request reprint Gender and ethnic differences in red cell distribution width and its association with mortality among low risk healthy United state adults
    Sandip K Zalawadiya
    Division of Cardiology, Department of Internal Medicine, Detroit Medical Center, Wayne State University, Detroit, Michigan, USA
    Am J Cardiol 109:1664-70. 2012
  10. ncbi request reprint Therapeutic potential of vasopressin receptor antagonists
    Farhan Ali
    Heart Failure Program, Wayne State University, Detroit, Michigan, USA
    Drugs 67:847-58. 2007

Detail Information

Publications64

  1. doi request reprint Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia
    Jalal K Ghali
    Wayne State University, Detroit, Mich, USA
    Circulation 117:526-35. 2008
    ..The Study of Anemia in Heart Failure Trial (STAMINA-HeFT) is the largest multicenter, randomized, double-blind, placebo-controlled trial to date evaluating the effect of treating anemia in HF...
  2. ncbi request reprint The influence of symptoms and device detected atrial tachyarrhythmias on medical management: insights from A-HIRATE
    Jalal K Ghali
    University Health Center, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Pacing Clin Electrophysiol 30:850-7. 2007
    ..We report the influence of symptoms and device detected AT on pharmacological disease management...
  3. ncbi request reprint Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia
    Jalal K Ghali
    Division of Cardiology, Wayne State University, 4201 St Antoine, Detroit, Michigan 48201, USA
    J Clin Endocrinol Metab 91:2145-52. 2006
    ..Hyponatremia [serum sodium concentration ([Na(+)]), <135 mEq/liter] is the most common fluid and electrolyte abnormality among hospitalized patients. It is frequently caused by the inappropriate release of arginine vasopressin...
  4. ncbi request reprint Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial
    Jalal K Ghali
    University Health Center, Wayne State University, Detroit, MI 48201, USA
    Am J Cardiovasc Drugs 7:373-80. 2007
    ....
  5. doi request reprint Sex differences in response to chronic heart failure therapies
    Jalal K Ghali
    University Health Care Center, Wayne State University, 4201 St Antoine, 2E, Detroit, MI 48201, USA
    Expert Rev Cardiovasc Ther 6:555-65. 2008
    ..Future clinical trials should be conducted either exclusively in women or have a larger representation of women to insure the adequate assessment of the potential benefit versus risk in women...
  6. doi request reprint Mechanisms, risks, and new treatment options for hyponatremia
    Jalal K Ghali
    Wayne State University, Detroit, Michigan, USA
    Cardiology 111:147-57. 2008
    ..The AVP receptor antagonists (conivaptan, tolvaptan, lixivaptan, and satavaptan) are a new class of agents that have been shown to normalize serum [Na(+)] by promoting aquaresis - the electrolyte-sparing excretion of free water...
  7. doi request reprint Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial
    Jalal K Ghali
    Wayne State University, Detroit, MI 48201, USA
    J Card Fail 14:718-23. 2008
    ..The beneficial effects of aldosterone antagonist (spironolactone [SP]), however have not been adequately assessed in black patients with or without the use of FDC I/H...
  8. ncbi request reprint Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)
    Marie Galvao
    Congestive Heart Failure Program, Division of Cardiology, Montefiore Medical Center, 7th Floor, 3400 Bainbridge Avenue, Bronx, NY 10467, USA
    J Card Fail 12:100-7. 2006
    ..The impact of gender differences has not been well described in patients hospitalized with acute decompensated heart failure (ADHF)...
  9. doi request reprint Gender and ethnic differences in red cell distribution width and its association with mortality among low risk healthy United state adults
    Sandip K Zalawadiya
    Division of Cardiology, Department of Internal Medicine, Detroit Medical Center, Wayne State University, Detroit, Michigan, USA
    Am J Cardiol 109:1664-70. 2012
    ..In conclusion, blacks and men have significantly greater RCDWs compared to whites and women. Greater RCDW is associated with a greater risk of mortality in men compared to women, whereas no effect modification is observed by ethnicity...
  10. ncbi request reprint Therapeutic potential of vasopressin receptor antagonists
    Farhan Ali
    Heart Failure Program, Wayne State University, Detroit, Michigan, USA
    Drugs 67:847-58. 2007
    ..Ongoing clinical trials should further define the scope of the potential therapeutic role of VRAs...
  11. doi request reprint The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study
    Jalal K Ghali
    Detroit Medical Center Cardiovascular Institute, Detroit, MI 48201, USA
    Eur J Heart Fail 14:642-51. 2012
    ..Vasopressin receptor antagonists such as lixivaptan may provide effective volume unloading. This study assessed weight loss after 1 day and 8 weeks of treatment with lixivaptan in outpatients with HF and volume overload...
  12. doi request reprint Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Savi
    Phillip D Levy
    Department of Emergency Medicine and the Cardiovascular Research Institute, Wayne State University School of Medicine, 4201 St Antoine, Detroit, MI 48201, USA
    Am Heart J 159:222-230.e2. 2010
    ..How such an interaction may be influenced by underlying etiology of HF and whether it extends to patients treated with angiotensin receptor blockers (ARBs), however, are not known...
  13. pmc Safety of symptom-limited cardiopulmonary exercise testing in patients with chronic heart failure due to severe left ventricular systolic dysfunction
    Steven J Keteyian
    Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI, USA
    Am Heart J 158:S72-7. 2009
    ..We hypothesized that exercise testing would be safe, as defined by a rate for all-cause death of <0.1 per 1,000 tests and a rate of nonfatal CV events <1.0 per 1,000 tests...
  14. doi request reprint The potential role for lixivaptan in heart failure and in hyponatremia
    Hammam D Zmily
    Detroit Medical Center Wayne State University, Harper University Hospital, 3990 John R, Suite 9370, Detroit, MI 48201, USA
    Expert Opin Investig Drugs 20:831-48. 2011
    ....
  15. ncbi request reprint Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]
    Farhan Ali
    Division of Cardiology, Department of Internal Medicine, Wayne State University, Detroit, Michigan, USA
    Cardiovasc Drug Rev 25:261-79. 2007
    ..Consideration should be given to further evaluation of its potential benefits in patients with acute decompensated heart failure...
  16. ncbi request reprint Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA
    JAMA 291:1963-71. 2004
    ..In contrast to diuretics, the vasopressin antagonist tolvaptan may increase net volume loss in heart failure without adversely affecting electrolytes and renal function...
  17. doi request reprint Red cell distribution width and mortality in predominantly African-American population with decompensated heart failure
    Sandip K Zalawadiya
    Detroit Medical Center, Wayne State University, Detroit, MI 47201, USA
    J Card Fail 17:292-8. 2011
    ..However, evidence is limited for its predictive value in the setting of patients hospitalized with decompensated heart failure (DHF) and no data are available for African Americans (AA)...
  18. ncbi request reprint Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure
    Jalal K Ghali
    Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Card Fail 13:769-73. 2007
    ..We performed a post hoc analysis to determine the influence of cardiac resynchronization therapy with a defibrillator (CRT-D) or without a defibrillator (CRT-P) on outcomes among diabetic patients with advanced heart failure (HF)...
  19. doi request reprint Guidelines, performance measures, and the practice of medicine: mind the gap
    Jalal K Ghali
    DMC Cardiovascular Institute, Detroit, MI, USA
    J Card Fail 16:915-8. 2010
    ....
  20. ncbi request reprint Heart failure guidelines, performance measures, and the practice of medicine: mind the gap
    Jalal K Ghali
    DMC Cardiovascular Institute, Wayne State University, Detroit, Michigan 48201, USA
    J Card Fail 17:90.e1-4. 2011
    ....
  21. doi request reprint The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF)
    Jalal K Ghali
    Detroit Medical Center, Detroit, Michigan, USA
    J Card Fail 15:310-8. 2009
    ..Limited information is available on the risk and impact of renal dysfunction on the response to beta-blockade and mode of death in systolic heart failure (HF)...
  22. ncbi request reprint Tolvaptan
    Jalal K Ghali
    Harper University Hospital, 3990 John R Street, 9 Webber Core, Detroit, MI 48201, USA
    Nat Rev Drug Discov 8:611-2. 2009
    ..In May 2009, tolvaptan (Samsca; Otsuka), a selective vasopressin V(2) receptor antagonist, was approved by the US FDA for the treatment of clinically significant hypervolaemic and euvolaemic hyponatraemia...
  23. ncbi request reprint A perspective on re-evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile
    Kirkwood F Adams
    Departments of Medicine and Radiology, School of Medicine, Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Eur J Heart Fail 16:483-93. 2014
    ..These findings suggest digoxin should have a more prominent therapeutic role in patients with heart failure and reduced ejection fraction. ..
  24. pmc Tolvaptan, hyponatremia, and heart failure
    Hammam D Zmily
    Wayne State University Detroit Medical Center, Detroit, MI, USA
    Int J Nephrol Renovasc Dis 4:57-71. 2011
    ....
  25. ncbi request reprint Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia
    Jalal K Ghali
    Detroit Medical Center Cardiovascular Institute, Clinical Cardiology, 3990 John R Street, Suite 9370, Detroit, MI 48201, USA
    IDrugs 13:782-92. 2010
    ..Ongoing phase III trials will determine the role of lixivaptan in the management of hyponatremia, especially when associated with heart failure...
  26. pmc Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure
    Larry A Allen
    Division of Cardiology, University of Colorado Denver, Aurora, CO, USA
    J Card Fail 16:230-8. 2010
    ..Our study sought to validate the prognostic value of RDW in heart failure and to explore the potential mechanisms underlying this association...
  27. pmc Relationship of Doppler-Echocardiographic left ventricular diastolic function to exercise performance in systolic heart failure: the HF-ACTION study
    Julius M Gardin
    St John Hospital and Medical Center, Detroit, MI Hackensack University Medical Center, Hackensack, NJ 07601, USA
    Am Heart J 158:S45-52. 2009
    ..Although in animal models diastolic dysfunction is associated with worsening exercise capacity and prognosis, information regarding these relationships in patients with established systolic heart failure (HF) is sparse...
  28. doi request reprint Anemia and iron deficiency in heart failure
    Natasha P Arora
    Division of Cardiovascular Services, Saint John Hospital and Medical Center, 22101 Moross Road, Detroit, MI 48236, USA
    Heart Fail Clin 10:281-94. 2014
    ....
  29. doi request reprint Iron deficiency anemia in heart failure
    Natasha P Arora
    Detroit Medical Center, Wayne State University, Detroit, MI, USA
    Heart Fail Rev 18:485-501. 2013
    ..In this review, the etiology and relevance of iron deficiency, iron metabolism in the setting of HF, studies on iron supplementation in patients with HF and potential cardiovascular effects of subclinical iron overload are discussed...
  30. doi request reprint Anemia and heart failure
    Jalal K Ghali
    Harper University Hospital, 3990 John R Street, 9 Webber Core, Detroit, MI 48201, USA
    Curr Opin Cardiol 24:172-8. 2009
    ..The earlier enthusiasm for raising hemoglobin in heart failure has been followed by skepticism and concern of potential harm from using erythropoiesis-stimulating agents (ESAs)...
  31. doi request reprint Valvular perforation in left-sided native valve infective endocarditis
    Khaled Bachour
    Division of Cardiology, Wayne State University, Detroit, Michigan, USA
    Clin Cardiol 32:E55-62. 2009
    ..Left-sided native valve infective endocarditis (LNVIE) can result in mitral (MP) and aortic (AP) valve perforation, the prognostic significance of which remains poorly defined...
  32. doi request reprint Heart failure guidelines, performance measures, and the practice of medicine: mind the gap
    Jalal K Ghali
    DMC Cardiovascular Institute, Detroit, Michigan 48201, USA
    J Am Coll Cardiol 56:2077-80. 2010
    ....
  33. ncbi request reprint Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial
    Wilson S Colucci
    Cardiovascular Medicine, Boston University Medical Center, 88 E Newton St, Boston, MA 02118, USA
    Circulation 116:49-56. 2007
    ..We investigated whether beta-blocker therapy ameliorates left ventricular remodeling in asymptomatic patients with left ventricular systolic dysfunction...
  34. ncbi request reprint Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF
    Andras Janosi
    Cardiology Department, Szent János Teaching Hospital, Budapest, Hungary
    Am Heart J 146:721-8. 2003
    ..However, patients with chronic heart failure (CHF) were excluded from those trials. The purpose of this study was to assess the effect of beta-blockers in post-MI patients with CHF receiving contemporary management...
  35. ncbi request reprint Gender differences in advanced heart failure: insights from the BEST study
    Jalal K Ghali
    Cardiac Centers of Louisiana, Shreveport, Louisiana 71103, USA
    J Am Coll Cardiol 42:2128-34. 2003
    ..The goal of this study was to determine the influence of gender on baseline characteristics, response to treatment, and prognosis in patients with heart failure (HF) and impaired left ventricular ejection fraction (LVEF)...
  36. ncbi request reprint Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure
    Prakash C Deedwania
    University of California, San Francisco School of Medicine, San Francisco, CA, USA
    Eur Heart J 25:1300-9. 2004
    ..To study the efficacy and tolerability of beta-blockade in elderly patients with heart failure in the MERIT-HF study...
  37. ncbi request reprint Sex-related differences in heart failure and beta-blockers
    Jalal K Ghali
    Clinical Research, Cardiac Centers of Louisiana, 2551 Greenwood Road, Suite 350, Shreveport, LA 71103, USA
    Heart Fail Rev 9:149-59. 2004
    ..Among the medications currently recommended for patients with systolic heart failure, beta-blockers have the strongest data supporting their efficacy in women...
  38. ncbi request reprint The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial
    Michael Domanski
    Clinical Trials Group, National Heart, Lung, and Blood Institute NIH, 6701 Rockledge Drive, Bethesda, MD 20892, USA
    J Am Coll Cardiol 42:914-22. 2003
    ..This was a retrospective analysis to determine the effect of diabetes on outcome in patients with advanced heart failure (HF), and to determine the effect of beta-blockade in patients with HF with and without diabetes mellitus...
  39. doi request reprint Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study
    Teresa De Marco
    University of California, San Francisco Medical Center, San Francisco, CA, USA
    J Card Fail 14:9-18. 2008
    ....
  40. ncbi request reprint Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF
    Prakash C Deedwania
    Department of Veterans Affairs Medical Center, Fresno, Calif, USA
    Am Heart J 149:159-67. 2005
    ....
  41. ncbi request reprint Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 111:3411-9. 2005
    ....
  42. ncbi request reprint Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02445, USA
    Am Heart J 150:257-62. 2005
    ..Angiotensin-converting enzyme (ACE) inhibition attenuates ventricular remodeling and improves ventricular function in heart failure patients. Vasopeptidase inhibition has shown similar effects in experimental models...
  43. ncbi request reprint Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure
    Derek C Angus
    Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Circulation 112:3745-53. 2005
    ..We assessed the resource use, costs of care, and cost-effectiveness of ISDN/HYD therapy in the A-HeFT trial population...
  44. ncbi request reprint Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial)
    Clyde W Yancy
    Baylor University Medical Center, Heart and Vascular Institute, Dallas, Texas, USA
    Am J Cardiol 100:684-9. 2007
    ..In conclusion, these results confirm the good compliance, tolerability, and responsiveness, with low mortality and improved symptoms, during treatment with ID/H observed in A-HeFT...
  45. ncbi request reprint Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF)
    Jalal K Ghali
    Cardiac Centers of Louisiana, Shreveport, LA 71103, USA
    Circulation 105:1585-91. 2002
    ..Underrepresentation of women in heart failure clinical trials has limited conclusions regarding the effect of various management strategies on survival in women with heart failure and decreased left ventricular ejection fraction (LVEF)...
  46. ncbi request reprint Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure
    Marc A Silver
    Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, Illinois 60453, USA
    J Am Coll Cardiol 39:798-803. 2002
    ....
  47. doi request reprint Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study)
    Nagesh S Anavekar
    Department of Cardiology, Austin Health, University of Melbourne, Melbourne, Australia
    Am J Cardiol 101:607-12. 2008
    ..53 (95% CI 1.24 to 1.88) increased risk of fatal and nonfatal CV outcomes. In conclusion, decreased right ventricular systolic function is a major risk factor for death, sudden death, HF, and stroke after MI...
  48. ncbi request reprint Anemia and poor prognosis in advanced heart failure
    Jalal K Ghali
    J Am Coll Cardiol 40:2204; author reply 2204. 2002
  49. ncbi request reprint Heart failure with preserved systolic function after myocardial infarction: a growing burden?
    Jalal K Ghali
    Am Heart J 145:575-8. 2003
  50. ncbi request reprint Hormone replacement therapy is associated with improved survival in women with advanced heart failure
    Joann Lindenfeld
    University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Am Coll Cardiol 42:1238-45. 2003
    ..We sought to determine whether hormone replacement therapy (HRT) is associated with an improved prognosis in women with advanced heart failure (HF) and systolic dysfunction...
  51. ncbi request reprint Diuretic use, progressive heart failure, and death in patients in SOLVD
    Jalal K Ghali
    J Am Coll Cardiol 43:1723; author reply 1723. 2004
  52. ncbi request reprint Cerebroprotection mediated by angiotensin II
    Jalal K Ghali
    J Am Coll Cardiol 44:2097; author reply 2097-8. 2004
  53. ncbi request reprint Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis
    Jalal K Ghali
    Cardiac Centers of Louisiana, 2551 Greenwood Road, Suite 350, Shreveport, LA 71103, USA
    J Card Fail 10:452-9. 2004
    ....
  54. ncbi request reprint Influence of pretreatment systolic blood pressure on benefit from carvedilol in severe chronic heart failure patients
    Jalal K Ghali
    J Am Coll Cardiol 45:809; author reply 809-10. 2005
  55. ncbi request reprint Beta-blockers in selected heart failure populations
    Jalal K Ghali
    Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA
    Curr Heart Fail Rep 2:100-5. 2005
    ..There is strong support in the literature for the use of selective beta-blockers in patients with mild to moderate chronic obstructive pulmonary disease and encouraging data on their use in patients with mild to moderate PVD...
  56. ncbi request reprint There is still hope for multifaceted intervention in heart failure
    Jalal K Ghali
    Am Heart J 152:e43; author reply e45. 2006
  57. ncbi request reprint Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure
    Joann Lindenfeld
    Department of Medicine, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262, USA
    Circulation 115:204-12. 2007
    ..We sought to examine the outcomes of NYHA class IV patients enrolled in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial to assess the potential benefits of CRT and CRT-D...
  58. ncbi request reprint A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function
    Jalal K Ghali
    Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA
    Am J Cardiol 99:47A-56A. 2007
    ..This study suggests that istaroxime is potentially useful in the treatment of HF and may offer a unique treatment for systolic and/or diastolic dysfunction. Additional studies are under way to further define its utility in acute HF...
  59. ncbi request reprint Asymptomatic atrial fibrillation in pacemaker recipients: incidence, progression, and determinants based on the atrial high rate trial
    Michael V Orlov
    Tufts University School of Medicine, Boston, Massachusetts 02135, USA
    Pacing Clin Electrophysiol 30:404-11. 2007
    ....
  60. ncbi request reprint Hyponatraemia in heart failure: a call for redefinition
    Jalal K Ghali
    Eur Heart J 28:920-1. 2007
  61. ncbi request reprint Hydralazine and nitrates: beyond race and ethnicity
    Jalal K Ghali
    J Card Fail 13:238. 2007
  62. ncbi request reprint Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study
    Jens Jakob Thune
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Soc Echocardiogr 19:1462-5. 2006
    ..Left ventricular (LV) ejection fraction (EF) and wall-motion index (WMI) have both been shown to be independent predictors of outcome after myocardial infarction (MI)...
  63. ncbi request reprint The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study
    Anil Verma
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1238-45. 2007
    ..The purpose of this study was to determine whether alterations in cardiac structure or function contribute to the increased risk associated with renal impairment after myocardial infarction (MI)...
  64. ncbi request reprint Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study
    Andrew J Burger
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass 02215, USA
    Am Heart J 144:1102-8. 2002
    ..In this randomized, multicenter trial, we compared the safety and clinical effectiveness of the cardiac hormone nesiritide (human B-type natriuretic peptide) with dobutamine in hospitalized patients with decompensated CHF...